Generics and biosimilars rarely dominate broker conversations, yet they drive some of the most dependable pharmacy savings available to employers. While much of the market remains fixated on pipeline risk and brand pricing volatility, these alternatives quietly reduce spend year after year without compromising clinical integrity.
For brokers advising cost-constrained employers, this matters. Pharmacy remains one of the hardest benefit categories to forecast, explain, and control. Generics and biosimilars offer something brokers value deeply: savings that are measurable, repeatable, and defensible in front of clients.
The Scale of the Opportunity
In 2024, generics and biosimilars delivered an estimated $467 billion in savings across the U.S. healthcare system. Over the past decade, cumulative savings exceeded $3.4 trillion. Nearly 90 percent of prescriptions filled today are generic or biosimilar products, yet they represent only about 12 percent of total drug spend.
Medicare beneficiaries saved an average of $2,600 per person in a single year. These numbers matter to brokers because they demonstrate that affordability is already being achieved in parts of the market. The challenge lies in extending that success into high-cost categories where spend concentration is highest.
Why Generics Still Matter to Employers
Generic drugs create value through competition. Once exclusivity ends, multiple manufacturers enter the market and prices fall rapidly. Lower prices improve adherence and reduce downstream medical costs tied to abandonment and underuse.
For employers, this translates into stabilized pharmacy trend and fewer surprises at renewal. For brokers, it creates a credible narrative that cost containment does not require benefit disruption or aggressive utilization management.
Biosimilars and High-Cost Drug Risk
Oncology, immunology, and inflammatory conditions represent some of the fastest-growing cost drivers in employer plans. Utilizing biosimilars is a clear way to make a dent in specialty pharmacy spend.
Biosimilars meet rigorous FDA standards for safety, efficacy, and clinical comparability, yet adoption remains uneven. Prescriber hesitation, benefit design complexity, and contracting dynamics all slow utilization. Each delay preserves high brand pricing and magnifies employer exposure to specialty trend. From a broker perspective, this is a missed opportunity. Biosimilars offer one of the few levers capable of bending specialty spend without limiting access or narrowing networks.
Adoption Lags in the Real World
Education alone will not change prescribing behavior. Physicians operate under time pressure, clinical responsibility, and workflow constraints. Generic and biosimilar adoption accelerates when recommendations are trusted, clinically governed, and presented within normal care patterns.
Benefit designs that rely solely on formulary pressure or step therapy often generate friction without achieving durable change. Brokers see the result in frustrated clients and modest savings that fail to meet expectations.
What Brokers Can Do Differently
Brokers play a critical role in aligning employers with strategies that deliver measurable savings. That means adding frictionless formulary alignment strategies to smart plan design:
- Clear clinical governance
- Prescriber-appropriate communication
- Savings that are visible and defensible to employers
When those elements are present, biosimilars move from theoretical savings to realized financial impact.
Where RazorMetrics Fits
RazorMetrics’ biosimilar solution is built around physician-directed recommendations governed by our internal Pharmacy and Therapeutics Committee. Opportunities are identified using claims data and the latest clinical evidence, then delivered through normal clinical workflows without disrupting care.
For brokers, this approach matters. It preserves prescriber trust, protects member experience, and produces documented savings employers can understand and validate.
As employers face continued pressure from specialty drug inflation and unpredictable pipeline launches, brokers who bring clinically grounded biosimilar solutions position themselves as true cost-containment partners. The data already proves the value. Execution determines who captures it.
Contact RazorMetrics today to get started on your biosimilar solution.
